多西他赛与奥沙利铂联合氟尿嘧啶类药物治疗晚期胃癌的临床效果比较

摘要

Objective To observe and compare the efficacy and safety of docetaxel or oxaliplatin combined with fluorouracil drugs in the treatment of advanced gastric cancer.Methods A total of 80 patients with advanced gastric cancer were randomly divided into observation group and control group,with 40 cases per group.The patients in the control group were treated with docetaxel combined with fluorouracil drugs for chemotherapy,while the patients in the observation group was treated with oxaliplatin combined with fluorouracil drugs for chemotherapy.The clinical outcomes,the overall survival (OS),the progression free survival (PFS) and the adverse advents during treatment in the two groups were observed and compared.Results There were no statistically significant differences in the distribution of the clinical outcomes and the clinical efficiency between the two groups (P ＞ 0.05).There were no statistically significant differences in the estimated median values of OS and PFS between the two groups (P ＞ 0.05).The incidence of white blood cell declining of the patients in the observation group was significantly lower,while the incidence of peripheral neurotoxicity was significantly higher than that in the control group,and there were statistically significant differences between the two groups (P ＜ 0.05).Conclusion In the treatment of advanced gastric cancer,the application of docetaxel combined with fluorouracil drugs for chemotherapy or oxaliplatin combined with fluorouracil drugs for chemotherapy can achieve basically equal therapeutic effects,but there are differences in the adverse advents.Both of them are the effective alternative in chemotherapy for advanced gastric cancer.%目的 观察和对比多西他赛与奥沙利铂联合氟尿嘧啶类药物治疗晚期胃癌的疗效和安全性.方法 选取80例晚期胃癌患者作为研究对象,将其随机分为观察组和对照组,每组各40例,对照组患者给予多西他赛联合氟尿嘧啶类药物进行化疗,观察组患者给予奥沙利铂联合氟尿嘧啶类药物进行化疗.对2组患者临床疗效、总生存期(0S)、无进展生存期(PFS)、治疗期间不良反应进行观察和对比.结果 2组患者疗效分布及临床有效率的差异均无统计学意义(P＞0.05).2组患者的OS和FPS的中位数估计值的差异均无统计学意义(P＞0.05).对照组患者白细胞减少发生率显著高于观察组,外周神经毒性发生率显著低于观察组(P＜0.05).结论 在晚期胃癌的治疗中,应用多西他赛联合氟尿嘧啶类药物化疗方案和应用奥沙利铂联合氟尿嘧啶类药物化疗方案的疗效及患者预后基本相当,不良反应种类有所有差异,均为晚期胃癌化疗的有效备选方案.